SMILE (Small Incision Lenticule Extraction) in the DoD (Department of Defense)

Myopia Clinical Trial

Official title:

SMILE (Small Incision Lenticule Extraction) in the DoD (Department of Defense)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04072289
• Other study ID #: NMCSD-2016.0055
• Status: Recruiting
• Phase: N/A
• Start date: May 1, 2019
• Est. completion date: September 2024

Study information

• Verified date: April 2022
• Source: United States Naval Medical Center, San Diego
• Contact: Donna M. Murdoch, PhD
• Phone: 619-524-6737
• Email: donna.m.murdoch.ctr[@]mail.mil
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Use of the VisuMaxTM Femtosecond Laser Small-Incision Lenticule Extraction (SMILE) Procedure for the Correction of Myopia with or without Astigmatism study is a prospective, non-randomized, multicenter clinical study that will be conducted by the Navy Refractive Surgery Center, Naval Medical Center San Diego, CA in collaboration with the U.S. Air Force 59th Medical Wing, Wilford Hall Eye Center, TX, and the U.S. Army Warfighter Refractive Eye Surgery Program and Research Center, Fort Belvoir Community Hospital, VA.

Description:

Prospective, multicenter, open-label, non-randomized clinical trial with bilateral commercial treatment for FDA approved indications and unilateral treatments for investigational refractive errors. Data from each treated eye of subjects will be treated independently. Monovision treatments and retreatments of the study eye will not be allowed during the course of the study. Successful bilateral treatment is required for performance based testing and patient reported outcome testing. Subjects will be randomized into the 0.25 and 0.50 sphere only and spherical cylinder bins using a sequential alternating randomization with an equal number assigned to both bins. Other subjects will be assigned to the bins they qualify for as they are enrolled into the study. Appointments are given to patients requesting refractive surgery randomly.

Three military sites in the U.S.A.: Navy Refractive Surgery Center, Naval Medical Center San Diego, CA in collaboration with the U.S. Air Force 59th Medical Wing, Wilford Hall Eye Center, TX, and the U.S. Army Warfighter Refractive Eye Surgery Program and Research Center, Fort Belvoir Community Hospital, VA.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: September 2024
• Est. primary completion date: September 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

1. Male and female subjects age 22 years of age and older either active duty or dependents who are eligible for care;

2. Myopia from = 0 D to = -10.00 D with = -3.00 D cylinder and MRSE = -1.00 D to

= -11.50 D in the eye(s) to be treated;

3. A stable refraction for the past year, as demonstrated by a change in MRSE of = 0.50 D in the eyes to be treated;

4. A difference between cycloplegic and manifest refractions of

= 0.75 D spherical equivalent in both eye(s);

5. UCVA 2 lines worse than BCVA in the treated eye(s);

6. BSCVA at least 20/20 in the treated eye(s);

7. Discontinue use of contact lenses for at least 4 weeks (for hard lenses) or 2 weeks (for soft lenses) prior to the preoperative examination, and through entire study. The subject shall not be considered a contact lens wearer if they are not wearing hard contact lenses for 4 weeks or soft contact lenses for 2 weeks.

8. All contact lens wearers must demonstrate a stable refraction (within ±0.5 D), as determined by MRSE, on two consecutive examinations at least 7 days apart, in the eye(s) to be treated;

9. Central corneal thickness of at least 500 microns in the both eye(s);

10. Willing and able to return for scheduled follow-up examinations;

11. Able to provide written informed consent and follow study instructions in English.

12. Permission of the Commanding Officer for active duty subjects to receive refractive surgery and participate in the study.

Exclusion Criteria:

1. Manifest cylinder of more than -3.00 D;

2. Estimated treatment depth is less than 250 microns from the corneal endothelium;

3. Eye to be treated is targeted for monovision;

4. Keratometry readings via Sim-K values less than 40.00 D;

5. Abnormal corneal topographic findings, e.g. keratoconus, pellucid marginal degeneration in either eye;

6. History of or current anterior segment pathology, including cataracts in the eye to be treated;

7. Clinically significant dry eye syndrome unresolved by treatment in either eye;

8. Residual, recurrent, active ocular or uncontrolled eyelid disease, corneal scars or other corneal abnormality such as recurrent corneal erosion or severe basement membrane disease in the either eye;

9. Ophthalmoscopic signs of progressive or unstable myopia or keratoconus (or keratoconus suspect) in either eye;

10. Irregular or unstable (distorted/not clear) corneal mires on central keratometry images in either eye;

11. History of ocular herpes zoster or herpes simplex keratitis;

12. Deep orbits, strong blink, anxiety, pterygium, or any other finding suggesting difficulty in achieving or maintaining suction;

13. Difficulty following directions or unable to fixate;

14. Previous intraocular or corneal surgery of any kind in the eye to be treated, including any type of surgery for either refractive or therapeutic purposes;

15. History of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP > 21 mmHg in either eye;

16. History of diabetes, diagnosed autoimmune disease, connective tissue disease or clinically significant atopic syndrome;

17. Immunocompromised or requires chronic systemic corticosteroids or other immunosuppressive therapy that may affect wound healing;

18. History of known sensitivity to planned study medications;

19. Participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation;

20. Pregnant or lactating;

21. Anyone who has the potential to deploy or relocate during the follow-up period.

22. Systemic Medications that may confound the outcome of the study or increase risk to the subject, including but not limited to steroids, antimetabolites, etc.

23. Evidence of retinal vascular disease.

24. Glaucoma suspects by exam findings or family history.

Related Conditions & MeSH terms

• Astigmatism
• Myopia
• Surgical Wound

Intervention

Device:
• Visumax spherocylindrical treatment
treatment of low cylinder (<0.75D)

Locations

Country	Name	City	State
United States	Navy Warfighter Refractive Surgery Center	San Diego	California

Sponsors (2)

Lead Sponsor	Collaborator
United States Naval Medical Center, San Diego	Carl Zeiss Meditec, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measured postoperative refractive sphere and cylinder	manifest refraction spherical equivalent and manifest refractive cylinder refraction	12 months
Primary	Measured distance visual acuity	uncorrected visual acuity of 20/40 or better	12 months
Secondary	Measured difference in manifest refraction between 2 postoperative visits	95% of eyes <1.00D of MRSE change at latter of 2 postop refractions	latter of 2 postoperative refractions performed at least 3 months apart or at 3 months after surgery when compared with the 1 month interval
Secondary	Calculated rate of change in manifest refraction	mean rate of change of MRSE <0.5D/year (0.04D/mo)	latter of 2 postoperative refractions performed at least 3 months apart or at 3 months after surgery when compared with the 1 month interval
Secondary	Calculated decreased rate of change in manifest refraction	mean rate of change of MRSE decreases monotonically over time	latter of 2 postoperative refractions performed at least 3 months apart or at 3 months after surgery when compared with the 1 month interval
Secondary	Calculated stable rate of change in manifest refraction	95% CI for the mean rate of change includes zero	latter of 2 postoperative refractions performed at least 3 months apart or at 3 months after surgery when compared with the 1 month interval
Secondary	Measured best corrected visual acuity (method 1)	incidence of best spectacled correction worse than 20/40	12 months
Secondary	Measured best corrected visual acuity (method 2)	incidence of loss of >2 lines of best spectacled corrected visual acuity	12 months
Secondary	Measured refractive cylinder	incidence of induced cylinder >2D	12 months
Secondary	Incidence of adverse events	incidence of adverse events	12 months
Secondary	Incidence of patient reported visual phenomena	incidence of patient subjective symptoms	12 months
Secondary	Measured contrast sensitivity	change in contrast sensitivity from preop to postop	12 months